Skip to main content
EJNMMI Research

Table 1 Biodistribution of 111In-tilmanocept

From: Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 111In-tilmanocept

Organs

Non-blocked

Blocked

Blood

0.18 ± 0.02

0.2 ± 0.1

Heart

2.2 ± 0.3

1.22 ± 0.05*

Stomach

3.4 ± 0.4

1.7 ± 0.3*

Lung

1.2 ± 0.2

1.1 ± 0.1

Salivary glands

4.4 ± 0.5

1.8 ± 0.2*

Liver

22.6 ± 2.7

14.7 ± 1.3*

Pancreas

3.4 ± 0.2

1.2 ± 0.1*

Spleen

10.4 ± 2.0

6.2 ± 0.3*

Small intestine

1.9 ± 0.8

1.6 ± 0.5

Large intestine

1.3 ± 0.2*

2.5 ± 0.2

Fat

1.02 ± 0.58

0.24 ± 0.03

Skin

1.3 ± 0.2

1.2 ± 0.3

Muscle

0.7 ± 0.2

0.50 ± 0.04

Bone

2.5 ± 0.5

2.2 ± 0.7

Kidney

23.2 ± 5.7*

55.7 ± 4.0

Carcass

14.2 ± 1.7*

22.2 ± 1.1

GI

3.8 ± 1.7

2.9 ± 0.2

Aortaa

0.005 ± 0.000

N/A

  1. Biodistribution of 111In-tilmanocept (1.5 pmol/g of body weight) in female C57BL/6 mice, 1 h p.i. Blocked group was co-injected with blocking dose (10 nmol) of non-labelled tilmanocept. Data are presented as the mean percentage of injected dose per gram of tissue (%ID/g ± SD) except in carcass, gastrointestinal tract (GI) and aortas (dissected only from non-blocked mice, n = 2) where the uptakes are presented as %ID per whole sample.
  2. N/A not applicable
  3. *Show significantly lower uptake (p < 0.05)
  4. aWhole aortas from the sinotubular junction to aortic bifurcation were collected
Back to article page